A row broke out on Friday over a World Health Organization (WHO) clinical trial which concluded that the anti-viral drug remdesivir has little or no impact on a patient's chances of surviving Covid-19.

Gilead Sciences Inc said on Monday its antiviral drug remdesivir had mixed results in a late stage study of people with moderate Covid-19, as patients given a five-day course of the treatment showed

Takeda Pharmaceutical Co said on Wednesday it was developing a drug for high-risk patients infected with the new coronavirus, joining several other drugmakers seeking to develop a treatment for an illness that has killed over 3,000 people.